5 Hot-Running Health Insurance Stocks to Buy
Many of us are unhappy with our health insurers.

Many of us are unhappy with our health insurers. Premiums are high. Hospital bills can be large and deductibles for many policyholders are larger than ever.
But the world looks good if you own health insurance stocks. There are profits to be made managing government health care programs — Medicaid, public exchanges, the Children’s Health Insurance Program and Medicare. Because despite the confusion over health insurance, government health care expenditures continue to rise.
To wit, Medicare spending is projected grow 7.9% annually to 2023 with total expenditures of approximately $1.1 trillion. Meanwhile, Medicaid spending is estimated to grow 5.9% annually to 2023, when it will top $828 billion.
Here are five health insurance stocks to buy – all of which have advanced by double digits already in 2018. But don’t worry about being late to the party. There’s reason to expect more upside in these stocks because they need only to maintain a strategy at which they have proven adept: increase enrollments and contain medical costs.
Data is as of Oct. 15, 2018. Companies are listed in alphabetical order.

Centene
- Market value: $29.6 billion
No one paid much attention when Centene (CNC, $139.42) joined the Affordable Care Act exchanges in 2014. But now it is the largest ACA player with 1.6 million marketplace members and continues to earn substantial profits from this program.
Centene is no one-trick pony, however. It wins about 81% of the Medicaid contracts it bids on, based on an analysis by Wells Fargo analysts.
Success in gaining new business has showed up on the top and bottom lines alike. Last year’s earnings grew to $5.03 per share, up from $4.43 in 2016. But there’s more growth to come for this health insurance stock, say Bank of America analysts, who estimate 2018 EPS of $6.95 on eye-popping revenues of $69 billion.

Humana
- Market value: $44.8 billion
Humana (HUM, $317.01) is a well-known health insurer. Humana’s balance sheet includes almost $19 billion in cash against just $5.3 billion in total debt, enabling the company to manage the twists and turns of the health care business in the U.S., and capitalize on the opportunities these twists and turns create.
Regarding the latter: In April, Humana teamed up with private equity players TPG Capital and Welsh, Carson, Anderson & Stowe to purchase hospice provider Curo for $1.4 billion. That deal followed Human’s $4 billion acquisition of Kindred at Home, which when combined with Curo created the nation’s largest hospice provider.
Before and shortly after CVS Health (CVS) announced its acquisition of Aetna (AET) in December of last year, there was speculation that Humana might be the next takeover target. Since then, however, that spotlight has come off Humana, and instead, the health insurance company is eyeing stronger ties with Walmart (WMT); the two companies currently have a prescription drug partnership.
While these machinations play out, Humana’s Medicare Advantage continues to grow rapidly. In August, Humana raised its adjusted EPS guidance for fiscal 2018 from to approximately $14.15 from its previous range of $13.70 to $14.10. Bank of America/Merrill Lynch analysts expect Humana to benefit from a recent increase in Medicare Advantage rates.

Molina Healthcare
- Market value: $8.8 billion
Molina Healthcare (MOH, $138.57) is a managed care insurer that focuses on Medicaid. The growth in Medicaid is compelling (for insurers, but likely not for taxpayers), with government expenditures of $566 billion in 2016 projected to expand to $696 billion in 2020.
Molina reported second-quarter earnings in August that benefited from downsizing, improved productivity and debt reduction. Based on these improvements, management raised its EPS guidance substantially, from a range of $4-$4.50 per share to $7.39-$7.59, or an increase of 68%-85% on the higher and lower ends, respectively.
It’s not just Medicaid spending that is fueling optimism behind Molina and similar health insurance stocks. In 2017, a management shake-up resulted in Molina’s board letting go of CEO J. Mario Molina and CFO John Molina, the sons of founder C. David Molina. Joseph M. Zubretsky, former CEO of Hanover Insurance, took the reins during the fourth quarter of that year, and the company’s progress under his leadership during Q1 and Q2 of this year has been material.

UnitedHealth Group
- Market value: $259.0 billion
UnitedHealth Group (UNH, $260.25) is the largest health insurer in the United States, and the bulk of its business is tied to government programs that are growing at healthy rates. The stock has regularly hit new highs this year and is up 21% year-to-date.
About 10,000 baby boomers turn 65 daily and qualify for Medicare, which is UnitedHealth’s largest business segment, accounting for $66 billion of its $163 billion in revenues last year. UnitedHealth’s fastest-growing business, which it calls UnitedHealthcare Community & State, is tied to Medicaid spending (which is growing around 6% annually). Between 2015 and 2017, Community & State revenues jumped 29%, from $28.9 billion to $37.4 billion. These businesses are important because the employers and individual insurance division shrunk between 2016 and 2017, though it remains above 2015 levels.
Analysts are bullish on UNH because of its diversified product line, which they feel will enable it to adapt to changing government regulations and seize growth opportunities as they appear.

WellCare Health Plans
- Market value: $15.8 billion
WellCare Health Plans (WCG, $305.99) earns most of its revenue from running Medicare programs for the government. Remember” Medicare spending is growing at nearly 8%, according to the Centers for Medicare and Medical Services. Total spending in 2016 – the latest year for which actual figures are available – was $672 billion with projections for $1.1 trillion in 2023.
It’s a huge pie, and Wellcare is an able, acquisitive player. The company recently completed the acquisition of several Meridian health plan companies, giving it a top market position in two states, an accretive addition to earnings — according to the company’s guidance and analyst reports — and the option to enter the exchange business.
This comes on top of what Bank of America analysts forecast as robust organic growth, with 2017 earnings per share of $8.52 rising to $10.90 in 2018 – a roughly 28% improvement.
Website: gorillatrades.com
LinkedIn: Gorilla Trades
Phone: (866) 222-6639
Ken Berman has been buying and selling stocks since he was a teenager and met with early success trading then-fledgling biotech stocks like Amgen, Biogen and Immunex. He later became a broker and worked for two wire houses, where he developed a proprietary system for buying and selling equities. In 1999, Mr. Berman formalized his method under the Gorilla Trades name and now has subscribers in the U.S. and 55 other countries around the world.
-
-
What Is a Stock Split, and Why It Matters to You
A stock split can indicate that a company is healthy — but don't fall for the hype.
By Charles Lewis Sizemore, CFA • Published
-
Stock Market Today: Stocks Rally on Debt Ceiling News, Manufacturing Data
A slow start turned into a strong finish for stocks thanks to encouraging debt ceiling updates and the latest economic data.
By Karee Venema • Published
-
Can Stocks Picked by Artificial Intelligence Beat the Market? 3 Stocks to Watch
stocks An artificial intelligence stock-picking platform identifying high-potential equities has been sharp in the past. Here are three of its top stocks to watch over the next few months.
By Dan Burrows • Published
-
5 Great Places to Buy a Vacation Home
With remote work on the rise, more people are looking for a permanent getaway.
By Ellen Kennedy • Published
-
5 Stocks to Sell or Avoid Now
stocks to sell In a difficult market like this, weak positions can get even weaker. Wall Street analysts believe these five stocks should be near the front of your sell list.
By Dan Burrows • Published
-
The 9 Best Healthcare Stocks to Buy
The best healthcare stocks offer investors a defensive hedge in an uncertain market.
By Deborah Yao • Published
-
The 10 Cheapest Countries to Visit
Despite inflation, there are some areas where the strong dollar will definitely work in your favor. Travel, for example... we find the cheapest places to visit around the world this summer.
By Quincy Williamson • Last updated
-
Best AI Stocks to Buy: Smart Artificial Intelligence Investments
tech stocks AI stocks have been bloodied up in recent months, but the technology's relentlessly growing importance should see the sun shine on them again.
By Tom Taulli • Published
-
Amazon launches RxPass — its new subscription service for medication
Amazon's new program, RxPass, lets Prime members ship prescription medications to their homes for just $5 a month.
By Erin Bendig • Published
-
9 Best Stocks for Rising Interest Rates
stocks The Federal Reserve has been aggressive in its rate hiking, and it's likely not done yet. Here are nine of the best stocks for rising interest rates.
By Jeff Reeves • Published